Dnajc3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{infobox
|boxstyle = infobox-gene
|title = DNAJC3 Gene
|image =
|caption =
|gene_name = DNAJC3
|full_name = DnaJ Heat Shock Protein Family (Hsp40) Member C3
|alias = P58IPK, ERdj5
|chromosome = 13
|locus = 13q32.1
|ncbi_gene_id = 23054
|omim_id = 608377
|ensembl = ENSG00000137168
|uniprot = Q9Y2H1
|diseases = Diabetes Mellitus, Neurodegeneration, Ataxia, Hearing Loss
|inheritance = Autosomal Recessive
}}
DNAJC3, also known as P58IPK or ERdj5, is an endoplasmic reticulum (ER)-localized DnaJ chaperone with multiple cellular functions:
DNAJC3 is unique among ER chaperones as it:
DNAJC3 was originally identified as a diabetes susceptibility gene. Loss-of-function variants are associated with:
The ER stress pathway is critical for pancreatic β-cell function, and DNAJC3 deficiency leads to β-cell apoptosis.
DNAJC3 deficiency contributes to neurodegeneration through:
Studies show reduced DNAJC3 in brain tissue from AD and PD patients.
Biallelic DNAJC3 mutations cause a syndrome featuring:
DNAJC3 is expressed in tissues with high secretory capacity:
Neuronal expression is widespread, with particularly high levels in Purkinje cells and hippocampal neurons.
DNAJC3-based therapeutic strategies include:
The study of Dnajc3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.